Tranzyme Pharma has completed the chemistry-based drug discovery partnership and transferred the resulting compounds to Bristol-Myers Squibb to advance the development. The strategic collaboration leveraged Macrocyclic Template Chemistry, ...
Tags: Tranzyme Pharma, chemistry based drug, chemistry technology, company news
Edison Pharmaceuticals has started a phase 2B study, which will investigate new treatments for Friedreich's ataxia. The trial is entitled Safety and Efficacy Study of EPI-743 on Visual Function in Patients with Friedreich's Ataxia. It is ...
Tags: Edison Pharmaceuticals, disease severity, neuromuscular function
The US Food and Drug Administration has published two major requirements that it says will help prevent foodborne illnesses and improve food safety. The FDA on Friday (4 January) released two draft rule proposals that will allow it to ...
Tags: US Food and Drug Administration, foodborne illnesses, food safety
The US food industry has welcomed the publishing of two major requirements by the US Food and Drug Administration aimed at helping prevent foodborne illnesses and improve food safety. On Friday (4 January), the FDA released two draft rule ...
Tags: US, food industry, US Food and Drug Administration, foodborne illnesses
BioPhotas has gained the US marketing rights for its light therapy device,designed to treat acne,muscle and joint pain,muscle and joint stiffness,muscle spasm,arthritis and compromised local blood circulation,following the US Food and Drug ...
The US Food and Drug Administration(FDA)has announced two new food safety regulations that are aimed at preventing foodborne illness.The proposed rules implement the two-way FDA Food Safety Modernization Act(FSMA). The first rule requires ...
Tags: FDA, US Food, food safety regulations
Materials characterisation company Malvern Instruments Ltd has signed an exclusive distribution agreement with Affinity Biosensors LLC which will extend the range of solutions that Malvern offers to the biopharmaceutical sector.The ...
Tags: Malvern Instruments Ltd, Affinity Biosensors LLC, biopharmaceutical
PharmaIN and LAT Pharma have announced the issuance of FDA orphan-drug designation for terlipressin as treatment of ascites due to all etiologies apart from cancer. The companies are developing long-acting PHT101(PGC-C12E-Terlipressin)for ...
Tags: PharmaIN-LAT Pharma ascite therapy, FDA orphan-drug designation, PHT101
Famy Care has won final FDA approval for abbreviated new drug application (ANDA) of Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15mg/0.03mg, generic equivalent to Teva Branded Pharmaceutical Products' Nordette 28 tablets. Mylan ...
Tags: Medicine
EMD Serono, a subsidiary of Merck, and Pfizer have announced the FDA approval of Rebif Rebidose (interferon beta-1a) for the treatment of relapsing forms of multiple sclerosis (MS). Rebif Rebidose was designed as single-use auto-injector ...
The US Food and Drug Administration (FDA) has granted 510(k) approval to Alphatec Holdings' new products, Pegasus and ILLICO FS Facet Fixation systems. Pegasus, an anchored anterior cervical interbody device, offers single-step deployment ...
Tags: MIS Systems, Alphatec, FDA Approval, New Anterior Cervical Interbody
LGC Standards’ LoGiCal reference solutions are proving beneficial to the Eastern Finland Laboratory Centre Joint Authority Enterprise (ISLAB) laboratory at Kuopio University Hospital. ISLAB performs around eight million analyses ...
Tags: LGC Standards, healthcare
Scientists funded by Cancer Research UK are using virtual experiments in a bid to find the best methods for drug discovery. The findings have been published in the Nature Reviews Drug Discovery journal, with the work combining a unique ...
Tags: Cancer Research UK, virtual experiments, drug discovery, online database
The chairman and CEO of US retailer Safeway Inc, Steve Burd, has announced his intention to retire. Burd, who joined Safeway in 1992 as president, will step down at the company's annual stockholders meeting on 14 May. The group said it ...
Tags: Safeway, Steve Burd, retire, company news
Abbott has obtained regulatory approval for its XIENCE Xpedition Everolimus Eluting Coronary Stent system,designed for improving coronary artery luminal diameter in patients with symptomatic heart disease due to de novo native coronary ...
Tags: Abbott, FDA, Drug Eluting System, XIENCE, symptomatic heart disease